Full-Time

Director – CMC Project Management

Posted on 11/21/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$195k - $245kAnnually

Senior, Expert

San Carlos, CA, USA

This is a hybrid position.

Category
Project Management
Business & Strategy
Requirements
  • B.S. or M.S. or Ph.D. degree in Pharmaceutics, Chemistry, Chemical engineering or closely related field.
  • A minimum of 8 years CMC project management experience with small molecule development experience.
  • Experience working with global project teams and external development partners a plus.
  • Knowledge of current ICH guidelines, GMP guidelines, and related industry practices.
  • Working experience and knowledge of regulatory submissions (IND, IMPD, NDA and MAA).
  • Demonstrated strong cross-functional team and strategic leadership skills with people management experience a plus.
  • Demonstrated experience of working with complex development challenges with multidisciplinary teams to realize project objectives.
  • A self-starter with ability to work independently, deal with ambiguity and to develop a CMC development strategy in collaboration with other functions.
  • Ability to communicate effectively with team members with a diverse range of backgrounds.
  • Ability to interpret complex project information and deal with ambiguity.
  • Effective written and verbal communication skills and interpersonal skills.
Responsibilities
  • Provide project management support to CMC teams for projects ranging from Pre-IND through different phases of clinical development and commercialization.
  • Enable CMC leads and/ or functional leads in implementing comprehensive CMC strategies and development plans and driving the CMC timelines to meet project’s needs.
  • Collaborate with CMC lead(s) to plan and facilitate regular and effective CMC project meetings with structured agendas and accurate meeting minutes; follow up on action items.
  • Proactively identify potential key issues and communicate with key stakeholders and management in a timely manner.
  • Participate in the CMC portfolio review process to support the growing pipeline and provide input to senior management.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?